Table 2.
Descriptive statistics for analyzed measurable traits in the studied patients by study arm and phase of the study
| Analyzed trait | Study arm | Phase of the study | Statistical parameter | Level of statistical significance (p-value) | ||||
|---|---|---|---|---|---|---|---|---|
| Ma | SD† | 95% CIb | Min. – max. | |||||
| Age (years) | 16,50 | 4,38 | 14,32-18,68 | 10–24 | a | b | ||
| Phosphor (mmol/L) | Calcitriol 0,5 mcg | Before treatment | 1,48 | 0,27 | 1,35-1,61 | 1,03-1,93 | = 0,021 | = 0,359 |
| After treatment | 1,35 | 0,20 | 1,26-1,45 | 1,04-1,70 | ||||
| Cholecalciferol 1000 IU | Before treatment | 1,53 | 0,23 | 1,42-1,64 | 1,05-1,87 | = 0,080 | ||
| After treatment | 1,44 | 0,18 | 1,35-1,54 | 1,21-1,82 | ||||
| Calcium (mg/dL) | Calcitriol 0,5 mcg | Before treatment | 3,50 | 2,60 | 2,28-4,72 | 2,22-9,80 | = 0,001 | = 0,041 |
| After treatment | 4,35 | 3,35 | 2,78-5,92 | 2,22-10,52 | ||||
| Cholecalciferol 1000 IU | Before treatment | 2,81 | 1,62 | 2,03-3,59 | 2,22-9,48 | = 0,185 | ||
| After treatment | 3,62 | 2,58 | 2,41-4,83 | 2,15-9,80 | ||||
| Parathormone (pg/ml) | Calcitriol 0,5 mcg | Before treatment | 35,64 | 17,61 | 27,40-43,88 | 16,99-89,12 | = 0,019 | = 0,208 |
| After treatment | 29,36 | 13,08 | 23,23-35,48 | 9,76-72,73 | ||||
| Cholecalciferol 1000 IU | Before treatment | 38,30 | 13,62 | 31,92-44,67 | 17,56-72,73 | = 0,334 | ||
| After treatment | 34,76 | 16,07 | 26,77-42,75 | 17,07-89,12 | ||||
| Urinary calcium/creatinine ratio (mg/dL: mg/dL) | Calcitriol 0,5 mcg | Before treatment | 0,262 | 0,195 | 0,168-0,356 | 0,030-0,800 | = 0,966 | = 0,232 |
| After treatment | 0,239 | 0,201 | 0,143-0,336 | 0,040-0,800 | ||||
| Cholecalciferol 1000 IU | Before treatment | 0,252 | 0,138 | 0,188-0,317 | 0,020-0,500 | = 0,050 | ||
| After treatment | 0,195 | 0,138 | 0,124-0,266 | 0,020-0,500 | ||||
| 25-OH D (ng/mL) | Calcitriol 0,5 mcg | Before treatment | 24,19 | 8,43 | 20,24-28,13 | 5,20-40,00 | = 0,125 | = 0,064 |
| After treatment | 28,19 | 9,75 | 23,63-32,76 | 8,10-42,90 | ||||
| Cholecalciferol 1000 IU | Before treatment | 24,13 | 9,86 | 19,52-28,74 | 9,40-48,30 | = 0,567 | ||
| After treatment | 24,97 | 10,86 | 19,89-30,06 | 8,00-49,00 | ||||
| IL-17A in the exhaled air (pg/mL) | Calcitriol 0,5 mcg | Before treatment | 0,475 | 0,515 | 0,234-0,717 | 0,050-1910 | = 0,008 | = 0,044 |
| After treatment | 0,384 | 0,429 | 0,184-0,585 | 0,070-1800 | ||||
| Cholecalciferol 1000 IU | Before treatment | 0,450 | 0,395 | 0,265-0,635 | 0,050-1910 | = 0,074 | ||
| After treatment | 0,290 | 0,195 | 0,199-0,382 | 0,070-0,710 | ||||
| IL-23 in the exhaled air (pg/mL) | Calcitriol 0,5 mcg | Before treatment | 9,39 | 6,40 | 6,39-12,38 | 2,12-30,72 | = 0,086 | = 0,399 |
| After treatment | 7,46 | 5,13 | 5,06-9,86 | 1,03-20,37 | ||||
| Cholecalciferol 1000 IU | Before treatment | 8,90 | 4,07 | 7,00-10,80 | 3,04-20,72 | = 0,001 | ||
| After treatment | 7,33 | 3,88 | 5,51-9,15 | 1,03–18,20 | ||||
(aM – mean, †SD – standard deviation, bCI – confidence interval. Mixed-effects regression models with robust standard errors, due to the small sample size, were performed: a – considering repeated measurements in the two separate studies; b – considering the above-mentioned repeated measurements, along with differences between the two studies and intra-subject correlation, on grounds of the cross-over study design. All statistical calculations were controlled for the studied patients’ age and sex)